PRL-8-53 HCl, ≥98%

You need to have an approved account to purchase this product.

PRL-8-53 is a nootropic research chemical derived from benzoic acid and phenylmethylamine with memory-enhancing effects, used in neuroscience research related to memory enhancement and protection against memory impairment.

Chemical Name	3-(2-benzylmethylaminoethyl)benzoic acid methyl ester hydrochloride
CAS Number	51352-87-5
Purity	≥98%
Form	White or off-white powder
Molecular Weight	319.83 g/mol
Melting Point	149-152℃
Molecular Formula	C₁₈H₂₁NO₂•HCl
Synonyms	Methyl 3-(2-(benzylmethylamino)ethyl)benzoate hydrochloride, 3-(2-benzylmethylaminoethyl) benzoic acid methyl ester hydrochloride

Notify me

Details

Precaution and Disclaimer:

This Material is Sold For Research Use Only. Terms of Sale Apply. Not for Human Consumption, nor Medical, Veterinary, or Household Uses.

Chemical Information:

CAS Number:	51352-87-5
Purity:	≥98%
Molecular Weight:	319.83 g/mol
Melting Point:	149-152℃
Molecular Formula:	C₁₈H₂₁NO₂•HCl
Synonyms:	Methyl 3-{2-[benzyl(methyl)amino]ethyl}benzoate hydrochloride, 3-(2-benzylmethylaminoethyl)benzoic acid methyl ester hydrochloride, PRL-8-53 HCl
PubChem CID:	70700868
SMILES:	CN(CCC1=CC=CC(=C1)C(=O)OC)CC2=CC=CC=C2.Cl

Technical Information:

Application:	PRL-8-53 is a nootropic research chemical derived from benzoic acid and phenylmethylamine with memory-enhancing effects, used in neuroscience research related to memory enhancement and protection against memory impairment.
Appearance:	White or off-white powder
Physical State:	Solid
Solubility:	Soluble to 25 mM in Ethanol, Soluble to 50 mM in Water.
Storage:	Store at room temperature or cooler, in a sealed airtight container, protected from heat, light and humidity.
Stability:	Stable for at least two years when stored as above.

Background:

PRL-8-53 (also known as Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate or PRL-8-53 HCl) is a Nootropic research compound. It was first synthesized by a medical chemistry professor, Nikolaus Hansl at Creighton University in the 1970s, during research into amino ethyl meta benzoic acid esters. [1] The compound is derived from benzoic acid and phenylmethylamine (Benzylamine) and has been shown to have memory-enhancing effects.

Modes of action:

The exact mechanism of action for PRL-8-53 is not yet fully understood. However, in the original patent research, it was indicated that dosages of up to 200 mg/kg did not possess stimulant properties. Furthermore, dosages of 20 mg/kg did not potentiate the effects of dextroamphetamine. [2]

Research has shown that PRL-8-53 exerts influence on the cholinergic system – by increasing dopamine signal transduction (“potentiates dopamine”) and partially inhibiting serotonin release. PRL-8-53 was also able to reverse the catatonic and hypnotic effects of reserpine. [1]

Other than this, there is still room for further research into the mechanism of action by which PRL-8-53 exerts its effects.

Further Scientific research:

Unfortunately, there is a very limited amount of scientific research that has been conducted on PRL-8-53 to this date. Independent replication of experiments conducted during the patent application would go a long way toward confirming PRL-8-53’s mechanisms and efficacy.

Clinical Reviews:

No reviews are available at this time.

Human studies:

A single study using human participants was conducted in 1978. The study included 47 healthy volunteers and was of fairly high statistical capacity – in a double-blind clinical format. The study’s aim was to measure the effects of 3-(2-benzylmethylaminoethyl) benzoic acid methyl ester hydrochloride (PRL-8-53 HCl) on learning and retention of verbal information in human subjects.[2] The study used the serial anticipation method – a technique for studying verbal learning that uses stimulus words and requires the participant to provide the next word in a series. [3]

Statistically significant (p-values between 0.001 and 0.01) increases in retention of verbal information were observed two hours after oral administration of 5mg PRL-8-53. Furthermore, this improvement in retention was still found to be significantly improved even 1 week after the initial dosage. The compound did not statistically improve motor reflexes or visual reaction time. [2]

Animal studies:

A variety of animal studies were conducted in the initial patent. These included standard avoidance response tests using negative reinforcement (electric shock) as well as maze tests using positive reinforcements (water reward). Results of the tests indicated increases in cognitive performance and learning capacity.

Furthermore, reproduction studies were carried out using the compound over two offspring generations and no evidence of malformation was observed. In dogs and monkeys, the compound was shown to be well tolerated in dosages of up to 50mg/kg. In higher mammals, the suggested oral administration range is between 0.01 to around 4mg/kg, with most preferable results occurring in the range of 0.05 to 1.2 mg/kg. [1] [4]

Toxicology cases:

PRL-8-53 is considered relatively non-toxic due to past studies. In mice, it has an oral LD₅₀of around 860 mg/kg. With an effective dosage of as low as 0.05 mg/kg, this gives PRL-8-53 a very high therapeutic index. In dogs, dosages above 8 mg/kg resulted in brief losses in blood pressure (hypotensive effects). In rats and mice, high doses suppress motor activity with an ED₅₀of around 160 mg/kg.[4]

References:

[1] Hansl NR. (1972). Substituted amino ethyl meta benzoic acid esters: US Patent 3870715 A. United States Patent Office.
[2] Hansl NR, Mead BT. (1978). PRL-8-53: Enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent. Psychopharmacology (Berl), 56(3):249-53.
[3] Serial Anticipation Method. (n.d.). OxfordReference.com. Available online at http://www.oxfordreference.com/view/10.1093/oi/authority.20110803100455881 [Accessed October 31, 2017]
[4] Hansl NR. (1974). A novel spasmolytic and CNS active agent: 3-(2-benzylmethylamino ethyl) benzoic acid methyl ester hydrochloride. Experientia, 30(3): 271–272.